Biogen

Phone: +1 781-464-2000

Formerly	Biogen Idec Inc. (2003–2015)
Type	Public company
Traded as	Nasdaq: BIIB NASDAQ-100 component S&P 500 component
Industry	Biotechnology
Founded	1978 (1978)
Founders	Kenneth Murray Phillip Allen Sharp Walter Gilbert Heinz Schaller Charles Weissmann
Headquarters	Cambridge, Massachusetts, U.S.
Key people	Stelios Papadopoulos (Chairman) Michel Vounatsos (CEO)
Products	Avonex, Fampyra, Plegridy, Tecfidera, Tysabri, Spinraza
Revenue	US$10.981 billion (2021)
Operating income	US$2.84 billion (2021)
Net income	US$1.727 billion (2021)
Total assets	US$23.877 billion (2021)
Total equity	US$10.96 billion (2021)
Number of employees	9,100 (2020)
Website	biogen.com

At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding in 1978 as one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases.

For detailed contact information visit location pages below.

Biogen's locations around the world

EuropeExpand

North AmericaExpand

AsiaExpand

South AmericaExpand

OceaniaExpand

New Zealand

Clinical Trials sponsored by Biogen

Biogen

Not yet recruiting

A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (STELLAR-2)

Muscular Atrophy, Spinal
Biogen

Recruiting

A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam (SOLAR)

Spinal Muscular Atrophy

United States
Biogen

Recruiting

A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone

Postpartum Depression

United States
Biogen

Recruiting

A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants

Healthy Volunteer

United States
Biogen

Recruiting

A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

China
Biogen

Recruiting

A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA) (STELLAR-1)

Muscular Atrophy, Spinal

United States
Biogen

Recruiting

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) (PROMINENT)

Primary Membranous Nephropathy

Australia, Taiwan, China, United States, Japan, Argentina, Brazil, Malaysia, India, South Korea
Biogen

Completed

A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different Ways

Healthy Volunteer

United States
Biogen

Active, not recruiting

A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND) (ASCEND)

Spinal Muscular Atrophy

United States, Hungary, Japan, Italy, Germany
Biogen

Enrolling by invitation

A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST LTE)

Subacute Cutaneous Lupus Erythematosus | Chronic Cutaneous Lupus Erythematosus

United States, Brazil, Spain, Taiwan, Canada, France, Germany, Japan, Italy, Colombia, United Kingdom, Serbia, Chile, Philippines, Bulgaria, China, Sweden, Switzerland, Mexico, South Korea, Argentina, Hungary, Slovakia, Poland, Portugal

Biogen

Biogen's locations around the world

Clinical Trials sponsored by Biogen

List of Pharmaceutical Companies by location